$0.92
-0.05 (-5.44%)
Open$0.97
Previous Close$0.97
Day High$0.97
Day Low$0.88
52W High$1.83
52W Low$0.48
Volume—
Avg Volume5.36M
Market Cap22.64M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,909.8% upside
Current
$0.92
$0.92
Target
$27.69
$27.69
$21.92
$27.69 avg
$40.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.87M | 4.80M | 3.54M |
| Net Income | -39,203,929 | -28,838,198 | -86,327 |
| Profit Margin | -667.8% | -634.4% | -2.4% |
| EBITDA | -36,850,122 | -28,612,681 | -134,724 |
| Free Cash Flow | — | — | -61,141 |
| Rev Growth | +22.4% | +22.4% | +8.8% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |